Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. J of Skin 2024, 8 (6), s445. https://doi.org/10.25251/skin.8.supp.445.